Preventing VTE in Cancer, Maintaining Low Bleeding Risk: Reduced-Dose Apixaban
Mario Balsa, medical oncology resident at Institut Català d’Oncologia, shared an insightful post on X:
” ‘New’ The New England Journal of Medicine (NEJM) study in 1,766 patients with cancer-associated VTE:
- Reduced-dose apixaban (2.5mg BID) vs full dose (5mg BID)
- VTE recurrence: 2.1% vs 2.8%
- Clinically relevant bleeding: 12.1% vs 15.6%
Same protection, less bleeding. Sometimes, less really is more!”
Effects of reduced dose of an oral anticoagulant on thromboembolic events and bleeding are discussed in the new study ”Extended Reduced-Dose Apixaban for Cancer-Associated Venous Thromboembolism” published by Isabelle Mahé et al. in the New England Journal of Medicine (NEJM).
In patients with active cancer and venous thromboembolism, extended treatment with reduced-dose apixaban was as effective as the full dose in preventing recurrent events.
Moreover, dose reduction resulted in fewer bleeding complications.
This supports reduced-dose apixaban as a safer alternative for long-term anticoagulation in this population.
Never miss the scientific advancements in the World of Hematology, read Hemostasis Today.
-
Aug 31, 2025, 14:26Diego Segura-Rodríguez Shares ESC/EACTS Consensus on Post-CABG Antithrombotic Therapy
-
Aug 31, 2025, 09:45Slow Uptake of Hemophilia Gene Therapies: Challenges in Access and Adoption
-
Aug 30, 2025, 14:43Abdulla A. Damluji Questions Evidence for Beta-Blockers After MI Without Heart Failure
-
Aug 30, 2025, 14:42BDCC Future Leaders ’26: Empowering Teens Like Sarada Venigalla to Share Their Stories
-
Aug 30, 2025, 14:39Michael Makris Shares French Regulatory Update: Marstacimab (Hympavzi) Not Recommended for Severe Haemophilia A or B
-
Aug 31, 2025, 12:39Lupus Anticoagulant and Antiphospholipid Syndrome: Insights from Local Practice
-
Aug 31, 2025, 10:55NEJM Study: Aspirin with Oral Anticoagulation Raises Risks in Chronic Coronary Syndrome
-
Aug 31, 2025, 07:29Marcin Kurzyna: ESC Guidelines on Pregnancy and Cardiovascular Disease Highlight Updates in VTE Treatment
-
Aug 30, 2025, 14:44Sarah C. Hull: Evidence Supports Plant-Forward Diets, Not Raw Milk or Beef Tallow Trends
-
Aug 30, 2025, 14:43Extended Low-Dose Apixaban Reduces Risk of Recurrent VTE: HI-PRO Trial Results
-
Aug 29, 2025, 09:03Vasculearn Network: New 2025 High Blood Pressure Guidelines Are Here
-
Aug 18, 2025, 23:56Dr. Arun V. J Invites You to His Lecture on ‘AI and Data Sciences in Transfusion Medicine’ at the AI in Healthcare Conclave. Register now!
-
Aug 18, 2025, 23:50Safe and Efficient Thrombectomy with Artix System: Clinical Insights from Neil Desai and Colleagues
-
Aug 16, 2025, 14:42Mark Crowther Honors Davide Matino for Leading Promising Hemophilia Trial at McMaster University
-
Aug 14, 2025, 10:28Impressive 95% Clot Removal in a VTE Case: Symphony16F and Symphony24F Catheters
-
Aug 30, 2025, 14:45Gordon’s Journey: 60 Years of Life After DVT Managed with Warfarin
-
Aug 29, 2025, 19:10Mount Sinai’s Dr. Krittika Pant to Present Watchman Device Thrombosis Analysis at ESC Congress 2025
-
Aug 29, 2025, 09:02Flora Peyvandi: Join the Hemostasis Community at BIC 2025 in Italy
-
Aug 26, 2025, 09:42David McIntosh Highlights Global Blood Shortages and Fresh vs Stored RBCs
-
Aug 23, 2025, 07:48Protecting Heart and Brain Health: Stroke Prevention in Women with Bleeding Disorders: NBDF